Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.72 USD
-0.15 (-5.23%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.62 -0.10 (-3.68%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATXI 2.72 -0.15(-5.23%)
Will ATXI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATXI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ATXI
Avenue Therapeutics Stockholders Approve Key Proposals
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics (ATXI) Gets a Buy from Maxim Group
Avenue Therapeutics GAAP EPS of $15.40 beats by $24.40
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)